Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving Average – What’s Next?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.75 and traded as low as $10.86. Enanta Pharmaceuticals shares last traded at $11.07, with a volume of 158,110 shares traded.

Analysts Set New Price Targets

A number of research firms recently commented on ENTA. Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Monday, April 20th. Finally, Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Trading Down 1.9%

The firm has a market cap of $321.92 million, a PE ratio of -4.27 and a beta of 0.97. The company’s 50-day moving average is $13.51 and its 200 day moving average is $13.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. The business had revenue of $17.16 million during the quarter, compared to the consensus estimate of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. On average, research analysts predict that Enanta Pharmaceuticals, Inc. will post -1.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently made changes to their positions in ENTA. AQR Capital Management LLC lifted its position in shares of Enanta Pharmaceuticals by 674.7% in the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after acquiring an additional 311,010 shares in the last quarter. Millennium Management LLC lifted its position in shares of Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after acquiring an additional 449,945 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after acquiring an additional 6,549 shares in the last quarter. Invesco Ltd. lifted its position in shares of Enanta Pharmaceuticals by 4.3% in the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 2,607 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Enanta Pharmaceuticals by 0.8% in the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after acquiring an additional 6,522 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.